Finalized Dutch conditional reimbursement system imminent
This article was originally published in SRA
Executive Summary
Formal criteria for what a Dutch conditional reimbursement system will finally look like are due to emerge at the end of the year, Nefarma, the Dutch pharmaceutical industry association says. However, delays in having a finalized system in place could be advantageous to companies with products that are at higher risk of losing reimbursement, said the association.